Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies

[1]  M. Kersten,et al.  Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Qihang Sun,et al.  Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies , 2021, Journal of Experimental & Clinical Cancer Research.

[3]  P. Jacqmin,et al.  Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model‐based approach , 2021, British journal of clinical pharmacology.

[4]  F. Locatelli,et al.  Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies , 2021, Frontiers in Immunology.

[5]  J. Zehnder,et al.  Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy , 2021, Blood advances.

[6]  He Huang,et al.  Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma , 2021, Frontiers in Oncology.

[7]  Cheng Cheng,et al.  Hemophagocytic lymphohistiocytosis‐like toxicity (carHLH) after CD19‐specific CAR T‐cell therapy , 2021, British journal of haematology.

[8]  A. Órfão,et al.  Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts , 2021, Journal for ImmunoTherapy of Cancer.

[9]  M. Sadelain,et al.  Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy , 2021, Nature Reviews Immunology.

[10]  Rosalie M Sterner,et al.  CAR-T cell therapy: current limitations and potential strategies , 2021, Blood Cancer Journal.

[11]  Michael R. Green,et al.  Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma , 2021, Blood.

[12]  F. Locatelli,et al.  The role of interferon‐gamma and its signaling pathway in pediatric hematological disorders , 2021, Pediatric blood & cancer.

[13]  J. Gauthier,et al.  Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL , 2020, Bone Marrow Transplantation.

[14]  A. Rapoport,et al.  Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes. , 2020, Neuro-oncology.

[15]  L. Meng,et al.  Macrophage, the potential key mediator in CAR-T related CRS , 2020, Experimental Hematology & Oncology.

[16]  H. Kotani,et al.  Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy , 2019, British journal of haematology.

[17]  D. Porter,et al.  Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  C. Doglioni,et al.  Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells , 2018, Nature Medicine.

[20]  Toshio Tanaka,et al.  Immunotherapeutic implications of IL-6 blockade for cytokine storm. , 2016, Immunotherapy.

[21]  C. Hunter,et al.  IL-6 as a keystone cytokine in health and disease , 2015, Nature Immunology.

[22]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[23]  G. Schulert,et al.  Macrophage activation syndrome and cytokine-directed therapies. , 2014, Best practice & research. Clinical rheumatology.

[24]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[25]  J. Szmydynger-Chodobska,et al.  Blood–Brain Barrier Pathophysiology in Traumatic Brain Injury , 2011, Translational Stroke Research.

[26]  N. Nishimoto,et al.  Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. , 2008, Blood.

[27]  A. Billiau,et al.  Modification of the anti‐CD3‐induced cytokine release syndrome by anti‐interferon‐γ or anti‐interleukin‐6 antibody treatment: Protective effects and biphasic changes in blood cytokine levels , 1993, European journal of immunology.